Prothena Corp. (NASDAQ:PRTA) shot up 1.4% during mid-day trading on Friday . The company traded as high as $50.92 and last traded at $50.05, with a volume of 175,804 shares changing hands. The stock had previously closed at $49.38.

A number of brokerages have recently issued reports on PRTA. Barclays PLC upped their target price on shares of Prothena Corp. from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, August 4th. Wedbush reaffirmed an “outperform” rating and issued a $77.00 target price on shares of Prothena Corp. in a report on Wednesday, August 3rd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $95.00 target price on shares of Prothena Corp. in a report on Monday, July 18th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Prothena Corp. in a report on Friday, June 10th. Finally, Zacks Investment Research raised shares of Prothena Corp. from a “sell” rating to a “hold” rating in a report on Friday, May 6th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Prothena Corp. has a consensus rating of “Buy” and a consensus target price of $76.60.

The company’s 50-day moving average price is $53.05 and its 200 day moving average price is $43.88. The company’s market cap is $1.72 billion.

Prothena Corp. (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by $0.27. The firm had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.39 million. The firm’s revenue was up 22.2% compared to the same quarter last year. Equities research analysts forecast that Prothena Corp. will post ($4.25) earnings per share for the current year.

In other news, insider Arthur W. Homan sold 9,375 shares of Prothena Corp. stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $52.14, for a total transaction of $488,812.50. Following the completion of the transaction, the insider now directly owns 9,375 shares in the company, valued at $488,812.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A hedge fund recently raised its stake in Prothena Corp. stock. Jennison Associates LLC raised its position in shares of Prothena Corp. (NASDAQ:PRTA) by 0.5% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 406,677 shares of the company’s stock after buying an additional 1,912 shares during the period. Jennison Associates LLC owned 1.29% of Prothena Corp. worth $27,699,000 at the end of the most recent reporting period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.